Genetically Engineered Biomimetic ATP-responsive Nanozyme for the Treatment of Cardiac Fibrosis

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Date 2025 Jan 8

PMID 39780203

Authors

Xueli Zhao

Yuze Qin

Bowen Li

Yue Wang

Jiao Liu

Bo Wang

Jia Zhao

Jiaqi Yin

Lanlan Zhang

Jing Li

Junzhe Huang

Kun Chen

Liwen Liu

Yuanming Wu

Affiliations

Soon will be listed here.

Abstract

Background: Cardiac fibrosis plays a critical role in the progression of various forms of heart disease, significantly increasing the risk of sudden cardiac death. However, currently, there are no therapeutic strategies available to prevent the onset of cardiac fibrosis.

Methods And Results: Here, biomimetic ATP-responsive nanozymes based on genetically engineered cell membranes are adapted to specifically recognize activated cardiac fibroblasts (CFs) for the treatment of cardiac fibrosis. By fusing the anti-FAP CAR genetically engineered cell membrane to zeolitic imidazole frameworks-90 (zif-90) cores loaded with antioxidant nanozymes CeO and siCTGF (siRNA targeting CTGF), these nanoparticles, called FM@zif-90/Ce/siR NPs, are demonstrated to effectively reduce the accumulation of myofibroblasts and the formation of fibrotic tissue, while restoring cardiac function.

Conclusions: These findings demonstrate that the combination of CeO and siCTGF has a beneficial curative effect on cardiac fibrosis, with significant translational potential.

Citing Articles

Complex regulation of cardiac fibrosis: insights from immune cells and signaling pathways.

Rao W, Li D, Zhang Q, Liu T, Gu Z, Huang L J Transl Med. 2025; 23(1):242.

PMID: 40022104 PMC: 11869728. DOI: 10.1186/s12967-025-06260-5.

References

Mo R, Jiang T, DiSanto R, Tai W, Gu Z . ATP-triggered anticancer drug delivery. Nat Commun. 2014; 5:3364. DOI: 10.1038/ncomms4364. View

Zhou Q, Zeng Y, Xiong Q, Zhong S, Li P, Ran H . Construction of CNA35 Collagen-Targeted Phase-Changeable Nanoagents for Low-Intensity Focused Ultrasound-Triggered Ultrasound Molecular Imaging of Myocardial Fibrosis in Rabbits. ACS Appl Mater Interfaces. 2019; 11(26):23006-23017. DOI: 10.1021/acsami.9b05999. View

He H, Han Q, Wang S, Long M, Zhang M, Li Y . Design of a Multifunctional Nanozyme for Resolving the Proinflammatory Plaque Microenvironment and Attenuating Atherosclerosis. ACS Nano. 2023; 17(15):14555-14571. DOI: 10.1021/acsnano.3c01420. View

Fang L, Murphy A, Dart A . A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease. Front Pharmacol. 2017; 8:186. PMC: 5382201. DOI: 10.3389/fphar.2017.00186. View

Kim Y, Lee Y, Lee N, Soh M, Kim D, Hyeon T . Ceria-Based Therapeutic Antioxidants for Biomedical Applications. Adv Mater. 2023; 36(10):e2210819. DOI: 10.1002/adma.202210819. View

Li B, Bai Y, Yion C, Wang H, Su X, Feng G . Single-Atom Nanocatalytic Therapy for Suppression of Neuroinflammation by Inducing Autophagy of Abnormal Mitochondria. ACS Nano. 2023; 17(8):7511-7529. DOI: 10.1021/acsnano.2c12614. View

Xiang K, Wu H, Liu Y, Wang S, Li X, Yang B . MOF-derived bimetallic nanozyme to catalyze ROS scavenging for protection of myocardial injury. Theranostics. 2023; 13(8):2721-2733. PMC: 10196836. DOI: 10.7150/thno.83543. View

Deng J, Wang K, Wang M, Yu P, Mao L . Mitochondria Targeted Nanoscale Zeolitic Imidazole Framework-90 for ATP Imaging in Live Cells. J Am Chem Soc. 2017; 139(16):5877-5882. DOI: 10.1021/jacs.7b01229. View

Rurik J, Aghajanian H, Epstein J . Immune Cells and Immunotherapy for Cardiac Injury and Repair. Circ Res. 2021; 128(11):1766-1779. PMC: 8171813. DOI: 10.1161/CIRCRESAHA.121.318005. View

10.

Kang S, Kim J, Ahn M, Kim J, Heo M, Min D . RNAi nanotherapy for fibrosis: highly durable knockdown of CTGF/CCN-2 using siRNA-DegradaBALL (LEM-S401) to treat skin fibrotic diseases. Nanoscale. 2020; 12(11):6385-6393. DOI: 10.1039/c9nr10305h. View

11.

Min H, Wang J, Qi Y, Zhang Y, Han X, Xu Y . Biomimetic Metal-Organic Framework Nanoparticles for Cooperative Combination of Antiangiogenesis and Photodynamic Therapy for Enhanced Efficacy. Adv Mater. 2019; 31(15):e1808200. DOI: 10.1002/adma.201808200. View

12.

Guo J, Yang Z, Lu Y, Du C, Cao C, Wang B . An antioxidant system through conjugating superoxide dismutase onto metal-organic framework for cardiac repair. Bioact Mater. 2021; 10:56-67. PMC: 8636922. DOI: 10.1016/j.bioactmat.2021.08.019. View

13.

Tillmanns J, Hoffmann D, Habbaba Y, Schmitto J, Sedding D, Fraccarollo D . Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. J Mol Cell Cardiol. 2015; 87:194-203. DOI: 10.1016/j.yjmcc.2015.08.016. View

14.

Travers J, Kamal F, Robbins J, Yutzey K, Blaxall B . Cardiac Fibrosis: The Fibroblast Awakens. Circ Res. 2016; 118(6):1021-40. PMC: 4800485. DOI: 10.1161/CIRCRESAHA.115.306565. View

15.

Aghajanian H, Kimura T, Rurik J, Hancock A, Leibowitz M, Li L . Targeting cardiac fibrosis with engineered T cells. Nature. 2019; 573(7774):430-433. PMC: 6752964. DOI: 10.1038/s41586-019-1546-z. View

16.

Gonzalez A, Schelbert E, Diez J, Butler J . Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. J Am Coll Cardiol. 2018; 71(15):1696-1706. DOI: 10.1016/j.jacc.2018.02.021. View

17.

Yang X, Tang Q, Jiang Y, Zhang M, Wang M, Mao L . Nanoscale ATP-Responsive Zeolitic Imidazole Framework-90 as a General Platform for Cytosolic Protein Delivery and Genome Editing. J Am Chem Soc. 2019; 141(9):3782-3786. DOI: 10.1021/jacs.8b11996. View

18.

Yuan A, Xia F, Bian Q, Wu H, Gu Y, Wang T . Ceria Nanozyme-Integrated Microneedles Reshape the Perifollicular Microenvironment for Androgenetic Alopecia Treatment. ACS Nano. 2021; 15(8):13759-13769. DOI: 10.1021/acsnano.1c05272. View

19.

Hoy S . Patisiran: First Global Approval. Drugs. 2018; 78(15):1625-1631. DOI: 10.1007/s40265-018-0983-6. View

20.

Zhang D, Liu H, Li C, Younis M, Lei S, Yang C . Ceria Nanozymes with Preferential Renal Uptake for Acute Kidney Injury Alleviation. ACS Appl Mater Interfaces. 2020; 12(51):56830-56838. DOI: 10.1021/acsami.0c17579. View